INT12290

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 2.04
Pain Relevance 1.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Dhfr) mRNA binding (Dhfr)
Anatomy Link Frequency
endothelium 2
Dhfr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Tetrahydrobiopterin 42 99.40 Very High Very High Very High
Enkephalin 4 98.52 Very High Very High Very High
methotrexate 55 98.08 Very High Very High Very High
bradykinin 4 98.04 Very High Very High Very High
Somatostatin 4 97.40 Very High Very High Very High
Inflammation 31 90.60 High High
ischemia 3 88.84 High High
rheumatoid arthritis 3 83.12 Quite High
Inflammatory mediators 5 74.96 Quite High
potassium channel 8 71.32 Quite High
Disease Link Frequency Relevance Heat
Cancer 3 98.72 Very High Very High Very High
Leukemia 1 98.36 Very High Very High Very High
Disease 8 97.60 Very High Very High Very High
INFLAMMATION 39 90.60 High High
Cv Unclassified Under Development 1 88.84 High High
Stress 9 88.16 High High
Myocardial Infarction 8 83.24 Quite High
Rheumatoid Arthritis 3 83.12 Quite High
Ventricular Remodeling 6 79.36 Quite High
Heart Rate Under Development 20 78.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The Bacillus subtilis dihydrofolate reductase (DHFR) gene was expressed in Escherichia coli.
Gene_expression (expressed) of DHFR
1) Confidence 0.76 Published 1992 Journal J. Biochem. Section Abstract Doc Link 1639761 Disease Relevance 0 Pain Relevance 0
Thus, the DHFR is useful as a carrier protein for expressing small polypeptides, such as leucine enkephalin, bradykinin, and somatostatin.
Gene_expression (expressing) of DHFR associated with somatostatin, enkephalin and bradykinin
2) Confidence 0.76 Published 1992 Journal J. Biochem. Section Abstract Doc Link 1639761 Disease Relevance 0 Pain Relevance 0.20
Dihydrofolate reductase from Bacillus subtilis and its artificial derivatives: expression, purification, and characterization.
Gene_expression (expression) of Dihydrofolate reductase
3) Confidence 0.76 Published 1992 Journal J. Biochem. Section Title Doc Link 1639761 Disease Relevance 0 Pain Relevance 0.05
The Bacillus subtilis dihydrofolate reductase (DHFR) gene was expressed in Escherichia coli.
Gene_expression (expressed) of dihydrofolate reductase
4) Confidence 0.67 Published 1992 Journal J. Biochem. Section Abstract Doc Link 1639761 Disease Relevance 0 Pain Relevance 0
This principle was used both for dhfr and dhps genes.
Gene_expression (genes) of dhfr
5) Confidence 0.27 Published 2010 Journal Malar J Section Body Doc Link PMC2831903 Disease Relevance 0 Pain Relevance 0
The circled numbers indicate potential sites of intervention: 1, L-arginine supplementation. 2, Inhibition of protein arginine N-methyltransferase type I (PRMT-I) to prevent the formation of asymmetric dimethyl-L-arginine (ADMA). 3, Increased expression and/or activity of dimethylarginine dimethylaminohydrolase-2 (DDAH-2) to facilitate ADMA catabolism. 4, Inhibition of arginase-2 to prevent L-arginine metabolism. 5, Increased expression and/or activity of endothelial nitric oxide synthase (eNOS). 6, Design of drugs that evoke endothelium-dependent relaxations. 7, Enhanced expression and/or activity of guanosine triphosphate cyclohydrolase (GTPCH), the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis, or direct supplementation with BH4 or its precursor sepiapterin. 8, Enhanced expression and/or activity of dihydrofolate reductase (DHFR), involved in BH4 regeneration. 9, Scavengers of reactive oxygen species (ROS), antioxidants. 10, Inhibition of the activity and/or expression of enzymes that generate ROS, such as NAD(P)H oxidases (NOX), cyclooxygenases (COX), lipoxygenases (LOX), or cytochrome P450 monooxygenases (P450). 11, Enhanced expression and/or activity of enzymes that metabolize ROS, such as superoxide dismutase (SOD) or catalase (or, alternatively, synthesis of mimetics). 12, Stimulation of soluble guanylyl cyclase (sGC). 13, Activation of sGC. 14, Inhibition of phosphodiesterase-5 (PDE-5). 15, Inhibition of soluble epoxide hydrolase (sEH) to suppress degradation of epoxyeicosatrienoic acids (EETs). 16, Opening calcium-activated potassium channels of small, intermediate, or large conductance (SKCa, IKCa, BKCa). 17, Opening transient receptor potential channels (TRP).
Gene_expression (expression) of DHFR in endothelium associated with tetrahydrobiopterin, trp channel and potassium channel
6) Confidence 0.26 Published 2010 Journal Curr Hypertens Rep Section Body Doc Link PMC2910890 Disease Relevance 0.07 Pain Relevance 0.29
The circled numbers indicate potential sites of intervention: 1, L-arginine supplementation. 2, Inhibition of protein arginine N-methyltransferase type I (PRMT-I) to prevent the formation of asymmetric dimethyl-L-arginine (ADMA). 3, Increased expression and/or activity of dimethylarginine dimethylaminohydrolase-2 (DDAH-2) to facilitate ADMA catabolism. 4, Inhibition of arginase-2 to prevent L-arginine metabolism. 5, Increased expression and/or activity of endothelial nitric oxide synthase (eNOS). 6, Design of drugs that evoke endothelium-dependent relaxations. 7, Enhanced expression and/or activity of guanosine triphosphate cyclohydrolase (GTPCH), the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis, or direct supplementation with BH4 or its precursor sepiapterin. 8, Enhanced expression and/or activity of dihydrofolate reductase (DHFR), involved in BH4 regeneration. 9, Scavengers of reactive oxygen species (ROS), antioxidants. 10, Inhibition of the activity and/or expression of enzymes that generate ROS, such as NAD(P)H oxidases (NOX), cyclooxygenases (COX), lipoxygenases (LOX), or cytochrome P450 monooxygenases (P450). 11, Enhanced expression and/or activity of enzymes that metabolize ROS, such as superoxide dismutase (SOD) or catalase (or, alternatively, synthesis of mimetics). 12, Stimulation of soluble guanylyl cyclase (sGC). 13, Activation of sGC. 14, Inhibition of phosphodiesterase-5 (PDE-5). 15, Inhibition of soluble epoxide hydrolase (sEH) to suppress degradation of epoxyeicosatrienoic acids (EETs). 16, Opening calcium-activated potassium channels of small, intermediate, or large conductance (SKCa, IKCa, BKCa). 17, Opening transient receptor potential channels (TRP).
Gene_expression (expression) of dihydrofolate reductase in endothelium associated with tetrahydrobiopterin, trp channel and potassium channel
7) Confidence 0.26 Published 2010 Journal Curr Hypertens Rep Section Body Doc Link PMC2910890 Disease Relevance 0.07 Pain Relevance 0.29
High-dose (20–250 mg/kg) methotrexate (MTX) treatment has been indicated for the treatment of neoplastic diseases, such as acute lymphoblastic leukemia and solid cancers, due to its inhibitory effect on de novo purine and pyrimidine synthesis through dihydrofolate reductase.
Gene_expression (synthesis) of dihydrofolate reductase associated with leukemia, cancer, disease and methotrexate
8) Confidence 0.20 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2768010 Disease Relevance 1.90 Pain Relevance 0.64

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox